Eton Pharmaceuticals Inc (ETON)vsEli Lilly and Company (LLY)
ETON
Eton Pharmaceuticals Inc
$24.12
+2.29%
HEALTHCARE · Cap: $628.09M
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 81425% more annual revenue ($65.18B vs $79.95M). LLY leads profitability with a 31.7% profit margin vs -5.8%. LLY earns a higher WallStSmart Score of 78/100 (B+).
ETON
Hold35
out of 100
Grade: F
LLY
Strong Buy78
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 82.7% year-over-year
Strong operational efficiency at 21.0%
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Areas to Watch
Smaller company, higher risk/reward
Trading at 24.9x book value
ROE of -18.2% — below average capital efficiency
Earnings declined 12.6%
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ETON
The strongest argument for ETON centers on Revenue Growth, Operating Margin. Revenue growth of 82.7% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bear Case : ETON
The primary concerns for ETON are Market Cap, Price/Book, Return on Equity.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
ETON profiles as a hypergrowth stock while LLY is a growth play — different risk/reward profiles.
ETON carries more volatility with a beta of 0.97 — expect wider price swings.
ETON is growing revenue faster at 82.7% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 35/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eton Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and marketing pharmaceuticals for rare diseases. The company is headquartered in Deer Park, Illinois.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?